MA38698A1 - Système d'administration transdermique - Google Patents
Système d'administration transdermiqueInfo
- Publication number
- MA38698A1 MA38698A1 MA38698A MA38698A MA38698A1 MA 38698 A1 MA38698 A1 MA 38698A1 MA 38698 A MA38698 A MA 38698A MA 38698 A MA38698 A MA 38698A MA 38698 A1 MA38698 A1 MA 38698A1
- Authority
- MA
- Morocco
- Prior art keywords
- buprenorphine
- sensitive adhesive
- adhesive layer
- acid
- pressure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0246—Adhesive plasters or dressings characterised by the skin adhering layer
- A61F13/0256—Adhesive plasters or dressings characterised by the skin adhering layer characterized by the parametric properties of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
L'invention concerne un système thérapeutique transdermique pour l'administration transdermique de buprénorphine, comprenant une structure de couche auto-adhésive contenant de la buprénorphine comprenant a) une couche de support imperméable à la buprénorphine et b) une couche adhésive sensible à la pression contenant de la buprénorphine sur ladite couche de support imperméable à la buprénorphine, la couche adhésive comprenant a) au moins un adhésif sensible à la pression à base de polymère, b) une quantité efficace de façon analgésique de base de buprénorphine ou d'un sel pharmaceutiquement acceptable de celle-ci, c) une substance augmentant la viscosité dans une quantité d'environ 0,1 % à environ 8 % de ladite couche adhésive sensible à la pression contenant de la buprénorphine et d) un acide carboxylique choisi dans le groupe consistant en acide oléique, acide linoléique, acide linolénique, acide lévulinique et leurs mélanges, dans une quantité suffisante de telle sorte que ladite quantité efficace de façon analgésique de buprénorphine y est solubilisée pour former un mélange comprenant ladite substance augmentant la viscosité, et le mélange contenant l'acide carboxylique, la buprénorphine et la substance augmentant la viscosité formant des dépôts dispersés dans ledit adhésif sensible à la pression, et ladite couche adhésive sensible à la pression contenant de la buprénorphine étant la couche de contact avec la peau.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361830975P | 2013-06-04 | 2013-06-04 | |
PCT/EP2014/061567 WO2014195352A1 (fr) | 2013-06-04 | 2014-06-04 | Système d'administration transdermique |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38698A1 true MA38698A1 (fr) | 2017-02-28 |
MA38698B1 MA38698B1 (fr) | 2017-10-31 |
Family
ID=51022809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38698A MA38698B1 (fr) | 2013-06-04 | 2014-06-04 | Système d'administration transdermique |
Country Status (34)
Country | Link |
---|---|
US (6) | US20160008294A1 (fr) |
EP (2) | EP3106153A1 (fr) |
JP (1) | JP6559121B2 (fr) |
KR (1) | KR102302505B1 (fr) |
CN (1) | CN105377245B (fr) |
AP (1) | AP2015008920A0 (fr) |
AR (1) | AR096521A1 (fr) |
AU (1) | AU2014276910B2 (fr) |
BR (1) | BR112015029920A2 (fr) |
CA (1) | CA2914425C (fr) |
CL (1) | CL2015003377A1 (fr) |
CR (1) | CR20150647A (fr) |
CY (1) | CY1118054T1 (fr) |
DE (1) | DE112014002664T5 (fr) |
DK (1) | DK2810646T3 (fr) |
EA (1) | EA201592246A1 (fr) |
ES (1) | ES2599802T3 (fr) |
GB (1) | GB2529789A (fr) |
HK (2) | HK1204766A1 (fr) |
HU (1) | HUE031662T2 (fr) |
LT (1) | LT2810646T (fr) |
MA (1) | MA38698B1 (fr) |
MX (1) | MX362614B (fr) |
NI (1) | NI201500170A (fr) |
PE (1) | PE20160002A1 (fr) |
PH (1) | PH12015502550A1 (fr) |
PL (1) | PL2810646T3 (fr) |
PT (1) | PT2810646T (fr) |
SG (1) | SG11201509218SA (fr) |
SI (1) | SI2810646T1 (fr) |
TN (1) | TN2015000493A1 (fr) |
TW (1) | TW201509416A (fr) |
WO (1) | WO2014195352A1 (fr) |
ZA (1) | ZA201509309B (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
CN104114161A (zh) | 2011-12-12 | 2014-10-22 | Lts勒曼治疗系统股份公司 | 包含丁丙诺啡的经皮递送系统 |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
WO2014195352A1 (fr) | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Système d'administration transdermique |
BR112015032929B1 (pt) | 2013-07-03 | 2022-08-23 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico |
US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
CN106456566B (zh) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
US10406152B2 (en) | 2015-03-10 | 2019-09-10 | Rhodes Technologies | Acetate salt of buprenorphine and methods for preparing buprenorphine |
US20180256562A1 (en) * | 2015-09-14 | 2018-09-13 | Amneal Pharmaceuticals Llc | Transdermal Delivery System |
AR102214A1 (es) * | 2015-10-08 | 2017-02-15 | Amarin Tech S A | Un dispositivo para la administración transdermal de buprenorfina |
US10486690B2 (en) * | 2016-12-14 | 2019-11-26 | Bendix Commerical Vehicle Systems, Llc | Front end motor-generator system and hybrid electric vehicle operating method |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
US20180221297A1 (en) * | 2017-02-03 | 2018-08-09 | Kirti H. Valia | System and Method for Improving Adhesion of Transdermal Delivery Devices |
CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
BR112020003314A2 (pt) * | 2017-09-04 | 2020-08-25 | Lts Lohmann Therapie-Systeme Ag | sistema de liberação transdérmico incluindo um emulsificante |
WO2019064026A1 (fr) | 2017-09-29 | 2019-04-04 | Orexo Ab | Nouvelles compositions pharmaceutiques |
WO2019166572A1 (fr) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase |
US20210000755A1 (en) | 2018-03-13 | 2021-01-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer |
AU2019261403A1 (en) * | 2018-04-25 | 2020-11-12 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
WO2019243452A1 (fr) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Système thérapeutique transdermique contenant de l'asénapine |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
CN113952319A (zh) * | 2021-11-30 | 2022-01-21 | 烟台大学 | 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
CA2002299A1 (fr) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Composes pour l'administration transdermique de sels de buprenorphine |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
DE3939376C1 (fr) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19738855C2 (de) * | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
DE19958554C2 (de) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung |
HU229085B1 (en) * | 1999-07-02 | 2013-07-29 | Lohmann Therapie Syst Lts | Microreservoir system on the basis of polysiloxanes and ambiphilic solvents |
CN1423559A (zh) | 2000-02-08 | 2003-06-11 | 欧罗赛铁克股份有限公司 | 包含阿片样激动剂和拮抗剂的控释组合物 |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
WO2002083135A2 (fr) | 2001-02-16 | 2002-10-24 | Grünenthal GmbH | Utilisation de la buprenorphine pour la production de systemes de delivrance transdermique servant au traitement de l'incontinence urinaire, et specialement de l'incontinence urinaire due a l'urgence urinaire |
DE10141651B4 (de) | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
AU2002350207A1 (en) | 2001-11-19 | 2003-06-10 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
US20050118245A1 (en) | 2002-03-27 | 2005-06-02 | Wilsmann Klaus M. | Assembled unit consisting of individually separable, transdermal, therapeutic systems |
DE10213772A1 (de) | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen |
US20050191340A1 (en) | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
DK1526848T3 (da) | 2002-08-09 | 2007-10-22 | Gruenenthal Gmbh | Opiod-receptorantagonister i transdermale systemer med buprenorphin |
SI1572167T1 (sl) | 2002-12-13 | 2008-12-31 | Euro Celtique Sa | Transdermalni buprenorfinski dozirni reĹľim za analgezijo |
RU2324372C2 (ru) | 2003-03-25 | 2008-05-20 | Моринда, Инк. | Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека |
PL219512B1 (pl) * | 2003-04-14 | 2015-05-29 | Lohmann Therapie Syst Lts | Plaster miejscowy, zastosowanie plastra miejscowego i sposób wytwarzania plastra miejscowego |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US8007737B2 (en) * | 2004-04-14 | 2011-08-30 | Wyeth | Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices |
DE102004019916A1 (de) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster |
DE102004045599A1 (de) | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen |
DE102004062647A1 (de) | 2004-12-21 | 2006-06-29 | Kronotec Ag | Holzfaserdämmstoffplatte bzw.- matte |
DE102004062614B4 (de) | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung |
DE102006026578B4 (de) | 2006-06-08 | 2009-01-08 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung |
DE102006054731B4 (de) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
DE102006054732B4 (de) | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
JP5235384B2 (ja) | 2007-11-08 | 2013-07-10 | リンテック株式会社 | 貼付シート |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
EP2366388A1 (fr) * | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Système thérapeutique transdermique non occlusif destiné à l'administration de buprenorphine |
DK2640389T3 (en) * | 2010-11-17 | 2015-03-09 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
CN104114161A (zh) | 2011-12-12 | 2014-10-22 | Lts勒曼治疗系统股份公司 | 包含丁丙诺啡的经皮递送系统 |
WO2014051128A1 (fr) | 2012-09-28 | 2014-04-03 | 株式会社 ケイ・エム トランスダーム | Timbre transdermique |
AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
WO2014195352A1 (fr) | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Système d'administration transdermique |
-
2014
- 2014-06-04 WO PCT/EP2014/061567 patent/WO2014195352A1/fr active Application Filing
- 2014-06-04 HU HUE14171110A patent/HUE031662T2/en unknown
- 2014-06-04 AR ARP140102182A patent/AR096521A1/es unknown
- 2014-06-04 TN TN2015000493A patent/TN2015000493A1/en unknown
- 2014-06-04 ES ES14171110.1T patent/ES2599802T3/es active Active
- 2014-06-04 SI SI201430078A patent/SI2810646T1/sl unknown
- 2014-06-04 PE PE2015002556A patent/PE20160002A1/es not_active Application Discontinuation
- 2014-06-04 PL PL14171110T patent/PL2810646T3/pl unknown
- 2014-06-04 TW TW103119370A patent/TW201509416A/zh unknown
- 2014-06-04 DK DK14171110.1T patent/DK2810646T3/en active
- 2014-06-04 SG SG11201509218SA patent/SG11201509218SA/en unknown
- 2014-06-04 PT PT141711101T patent/PT2810646T/pt unknown
- 2014-06-04 DE DE112014002664.6T patent/DE112014002664T5/de not_active Withdrawn
- 2014-06-04 GB GB1522307.6A patent/GB2529789A/en not_active Withdrawn
- 2014-06-04 BR BR112015029920A patent/BR112015029920A2/pt not_active Application Discontinuation
- 2014-06-04 EP EP16173124.5A patent/EP3106153A1/fr not_active Withdrawn
- 2014-06-04 CA CA2914425A patent/CA2914425C/fr active Active
- 2014-06-04 EA EA201592246A patent/EA201592246A1/ru unknown
- 2014-06-04 US US14/772,474 patent/US20160008294A1/en not_active Abandoned
- 2014-06-04 MX MX2015016123A patent/MX362614B/es active IP Right Grant
- 2014-06-04 AU AU2014276910A patent/AU2014276910B2/en active Active
- 2014-06-04 LT LTEP14171110.1T patent/LT2810646T/lt unknown
- 2014-06-04 JP JP2016517285A patent/JP6559121B2/ja active Active
- 2014-06-04 CN CN201480032321.8A patent/CN105377245B/zh active Active
- 2014-06-04 AP AP2015008920A patent/AP2015008920A0/xx unknown
- 2014-06-04 KR KR1020157037128A patent/KR102302505B1/ko active IP Right Grant
- 2014-06-04 EP EP14171110.1A patent/EP2810646B1/fr active Active
- 2014-06-04 MA MA38698A patent/MA38698B1/fr unknown
-
2015
- 2015-06-03 HK HK15105294.5A patent/HK1204766A1/zh unknown
- 2015-11-06 PH PH12015502550A patent/PH12015502550A1/en unknown
- 2015-11-17 CL CL2015003377A patent/CL2015003377A1/es unknown
- 2015-12-03 NI NI201500170A patent/NI201500170A/es unknown
- 2015-12-08 CR CR20150647A patent/CR20150647A/es unknown
- 2015-12-16 US US14/970,641 patent/US20160101100A1/en not_active Abandoned
- 2015-12-22 ZA ZA2015/09309A patent/ZA201509309B/en unknown
-
2016
- 2016-09-01 HK HK16110445.2A patent/HK1222135A1/zh unknown
- 2016-10-05 CY CY20161100988T patent/CY1118054T1/el unknown
-
2017
- 2017-01-24 US US15/414,138 patent/US20170128384A1/en not_active Abandoned
- 2017-11-22 US US15/820,978 patent/US20180092905A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,767 patent/US11529345B2/en active Active
- 2020-06-18 US US16/905,476 patent/US20200316055A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38698A1 (fr) | Système d'administration transdermique | |
BR112014014137A2 (pt) | sistema de liberação transdérmica compreendendo buprenorfina | |
TN2015000201A1 (en) | Transdermal delivery system | |
EP3207931A3 (fr) | Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre les médicaments provoquant des canalopathies | |
ATE389432T1 (de) | Vorrichtung zur transdermalen verabreichung von wirkstoffen | |
MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
MA39443A1 (fr) | Nouvelle formulation de méloxicam | |
MA48486B1 (fr) | Polymères liant les protons pour administration orale | |
RU2014102936A (ru) | Композиции противораковой вакцины, содержащей пептид wt1, для трансдермального введения | |
EP4238580A3 (fr) | Systeme d'administration transdermique comprenant un mediateur d'interface | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
EA201300648A1 (ru) | Трансдермальная терапевтическая система (tts), содержащая ротиготин | |
CL2019000753A1 (es) | Composición farmacéutica que comprende antagonista de receptor mineralocorticoide y su uso. | |
MA53418A1 (fr) | Préparation d'absorption transdermique contenant du donépézil stabilisé | |
RU2014102938A (ru) | Композиция вакцины для трансдермального введения | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
MA39304B1 (fr) | Formulations topiques d'héparine | |
ATE529127T1 (de) | Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung | |
JP2012520829A5 (fr) | ||
Quintás-Cardama et al. | The next generation of therapies for chronic myeloid leukemia | |
Ang | Duloxetine/tramadol | |
Pattamanuch et al. | NMDA Receptor Activity Contributes in Cellular DNA Damage Following Acetaminophen Hepatotoxicity and Offers Directions for Therapeutic Development: 50 | |
MA38310A1 (fr) | Combinaison médicamenteuse comprenant la phényléphrine et le paracétamol |